Immunotherapy for Prostate Cancer - Advanced Cancer Care

Immunotherapy for Prostate Cancer

Immunotherapy harnesses your immune system to fight prostate cancer. While immunotherapy has revolutionized treatment for many cancers, its role in prostate cancer is selective, working best for specific patient groups.

Overview of Immunotherapy for Prostate Cancer

What is Immunotherapy for Prostate Cancer?

Immunotherapy uses medicines or vaccines to stimulate your immune system to recognize and destroy cancer cells. Unlike chemotherapy or hormone therapy, immunotherapy trains your body's own defenses to attack prostate cancer.

Types of Immunotherapy for Prostate Cancer

• •Sipuleucel-T (Provenge)
  is the only FDA-approved immunotherapy vaccine for prostate cancer. This personalized treatment uses your own immune cells, activated outside the body, then reinfused to target prostate cancer cells expressing prostatic acid phosphatase (PAP).
• •Immune Checkpoint Inhibitors
  like pembrolizumab (Keytruda) block proteins that prevent immune cells from attacking cancer. While effective in many cancers, checkpoint inhibitors work for only a small subset of prostate cancer patients with specific genetic features.
• •Combination Approaches
  pairing immunotherapy with radiation, chemotherapy, or other treatments show promise in clinical trials.

When Immunotherapy is Needed

For Metastatic Castration-Resistant Prostate Cancer

Sipuleucel-T is approved for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer without visceral metastases. It's typically given before chemotherapy.

Immunotherapy for Stage 4 Prostate Cancer

Immunotherapy for stage 4 prostate cancer works best early in the metastatic castration-resistant phase, before significant symptoms develop.

For Select Genetic Subtypes

Pembrolizumab is FDA-approved for advanced prostate cancers with: High microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR), and High tumor mutational burden (TMB-H). These features occur in 2-5% of advanced prostate cancers. Testing determines if pembrolizumab might benefit you.

Treatment Process

Sipuleucel-T Administration

• •Week 1 (Leukapheresis)
  You undergo leukapheresis—a procedure where blood is drawn, white blood cells collected, and remaining blood returned to you. This takes 3-4 hours at a specialized center.
• •Cell Activation
  Your cells are shipped to a laboratory where they're activated with a protein fusion combining PAP (prostate cancer antigen) and an immune-stimulating factor.
• •Week 2 (Infusion)
  The activated cells are returned and infused intravenously over 60 minutes at your cancer center.
• •Full Course
  This process repeats three times over approximately one month (infusions at weeks 0, 2, and 4). The entire course involves three leukapheresis procedures and three infusions.

Pembrolizumab Administration

Pembrolizumab is given intravenously every 3 or 6 weeks (depending on dosing schedule). Each infusion takes 30 minutes. Treatment continues until disease progression or unacceptable side effects, potentially for months or years if beneficial. Regular monitoring includes PSA tests, imaging scans to assess cancer response, and blood tests checking for immune-related side effects.

Get Your Free Cancer Diet Plan & Report Analysis Now on WhatsApp

Talk to experts. Understand your reports. Get a personalized diet plan — all free to start.

Get My Free Plan on WhatsApp

India's First Cancer Care Management Platform

Free to start•Secure & private•No app download needed

Benefits and Risks

Benefits of Immunotherapy for Prostate Cancer

• •Extended survival with sipuleucel-T
  4.1-month median survival improvement (25.8 months vs 21.7 months), with 22% death risk reduction.
• •Durable responses with checkpoint inhibitors
  For MSI-H/dMMR or TMB-H tumors, pembrolizumab produces dramatic, long-lasting responses in approximately 50% of eligible patients.
• •Favorable side effect profile
  Sipuleucel-T causes primarily mild, temporary side effects—major advantage over chemotherapy.

Side Effects of Immunotherapy for Prostate Cancer

• •Sipuleucel-T Side Effects
  are generally mild. These include flu-like symptoms (chills, fever, fatigue, headache, muscle aches) in 50-75% of patients, lasting 1-3 days after each infusion and usually diminishing with subsequent doses. Nausea, injection site reactions, and joint aches can also occur. Serious side effects are rare.
• •Pembrolizumab Side Effects
  can be more significant. Immune-related inflammation can affect any organ, such as colitis (diarrhea), pneumonitis (cough), hepatitis (liver inflammation), thyroid dysfunction, rash, or arthritis. Fatigue is also common. Most immune-related side effects are manageable with steroids if caught early.

Aftercare and Recovery

Managing Side Effects

• •For sipuleucel-T
  Premedicate with acetaminophen and antihistamine before infusions. Rest as needed.
• •For pembrolizumab
  Report new symptoms promptly. Early detection allows prompt steroid treatment.
• •General advice
  Stay hydrated, maintain nutrition, and attend all monitoring appointments.

Cost of Immunotherapy for Prostate Cancer

Sipuleucel-T costs $90,000-$100,000 in the U.S. for three doses. Medicare and most insurance cover it. Pembrolizumab costs approximately $150,000-$175,000 annually in the U.S.

Immunotherapy for Prostate Cancer in India

Immunotherapy for prostate cancer in India: Sipuleucel-T has limited availability due to complex manufacturing requirements. Pembrolizumab is available at major centers, costing ₹15-25 lakhs ($18,000-$30,000) annually. Insurance coverage varies. Genetic testing for eligibility is available at leading pathology labs.

Success Rates and Life Expectancy

Sipuleucel-T extends median survival by 4.1 months. 36-month survival was 32% with sipuleucel-T versus 23% with placebo.

For pembrolizumab in MSI-H/dMMR or TMB-H cancers, response rates approach 50%, with many responses lasting years.

Why Choose Everhope

Everhope's immunotherapy program provides comprehensive evaluation including genetic testing for checkpoint inhibitor candidates, patient selection for optimal timing, and coordination with specialized centers. Our multidisciplinary team integrates immunotherapy strategically with other treatments. We track response through PSA monitoring and imaging, with rapid intervention for side effects.